Last reviewed · How we verify
AREXVY, ABRYSVO
AREXVY, ABRYSVO is a Recombinant glycoprotein vaccine Small molecule drug developed by National Heart, Lung, and Blood Institute (NHLBI). It is currently FDA-approved for Prevention of respiratory syncytial virus (RSV) disease in adults aged 60 years and older, Prevention of RSV-caused lower respiratory tract disease in infants born to vaccinated pregnant women.
AREXVY and ABRYSVO are recombinant glycoprotein F (RSVpreF3) vaccines that elicit immune responses against respiratory syncytial virus (RSV) to prevent RSV disease.
AREXVY and ABRYSVO are vaccines that have been studied in clinical trials for various conditions, including Lymphoma, Preventable Disease, Vaccine, and Respiratory Syncytial Virus (RSV), and have been administered in combination with Fluzone, Shingrix, and Flucelvax. The vaccines are being investigated in a study titled "Vaccine Responses in Patients With B Cell Malignancies" at the National Institutes of Health Clinical Center.
At a glance
| Generic name | AREXVY, ABRYSVO |
|---|---|
| Sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
| Drug class | Recombinant glycoprotein vaccine |
| Target | RSV fusion (F) glycoprotein, prefusion conformation |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
These vaccines contain a stabilized prefusion form of the RSV fusion (F) glycoprotein, which is a key target for neutralizing antibodies. By presenting this antigen, the vaccines stimulate both humoral and cellular immune responses that protect against RSV infection and disease severity. They are indicated for prevention of RSV-caused lower respiratory tract disease in older adults and infants.
Approved indications
- Prevention of respiratory syncytial virus (RSV) disease in adults aged 60 years and older
- Prevention of RSV-caused lower respiratory tract disease in infants born to vaccinated pregnant women
Common side effects
- Injection site pain
- Myalgia
- Fatigue
- Headache
- Injection site swelling
- Fever
Key clinical trials
- Addressing Unfunded Vaccines Through a Co-payment Mechanism in Pharmacies (NA)
- Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
- Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AREXVY, ABRYSVO CI brief — competitive landscape report
- AREXVY, ABRYSVO updates RSS · CI watch RSS
- National Heart, Lung, and Blood Institute (NHLBI) portfolio CI
Frequently asked questions about AREXVY, ABRYSVO
What is AREXVY, ABRYSVO?
How does AREXVY, ABRYSVO work?
What is AREXVY, ABRYSVO used for?
Who makes AREXVY, ABRYSVO?
What drug class is AREXVY, ABRYSVO in?
What development phase is AREXVY, ABRYSVO in?
What are the side effects of AREXVY, ABRYSVO?
What does AREXVY, ABRYSVO target?
Related
- Drug class: All Recombinant glycoprotein vaccine drugs
- Target: All drugs targeting RSV fusion (F) glycoprotein, prefusion conformation
- Manufacturer: National Heart, Lung, and Blood Institute (NHLBI) — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of respiratory syncytial virus (RSV) disease in adults aged 60 years and older
- Indication: Drugs for Prevention of RSV-caused lower respiratory tract disease in infants born to vaccinated pregnant women
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing